Veru Inc. outlined its cardiometabolic pipeline, highlighting enobosarm, an oral selective androgen receptor modulator, being developed in combination with a GLP-1 receptor agonist to support additional weight loss while preserving muscle and physical function in older adults with obesity. The company summarized data from its completed Phase 2b QUALITY trial in 168 patients with obesity taking semaglutide, where the primary endpoint of preservation of total lean body mass at 16 weeks was met, alongside reductions in fat mass and measures of physical function. Veru also described the planned Phase 2b PLATEAU study, a 68-week, double-blind trial in 200 non-diabetic patients aged 65 and older with BMI at or above 35, with total body weight as the primary endpoint and body composition and functional outcomes as key secondary measures, and noted sabizabulin as a program for atherosclerosis in stable coronary artery disease following completion of the Phase 2 QUALITY study in 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.